ESR1 and neoplasm: Neoadjuvant antihormonal therapy with an AI is a particularly attractive option for postmenopausal women who wish to attempt breast conservation and have strongly ER- and PgR-positive tumours that are ≥ 3 cm and have low proliferation rates.